Spots Global Cancer Trial Database for Quality of Life in Patients With Bladder Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Quality of Life in Patients With Bladder Cancer

Official Title: Bladder Cancer Prognosis Programme (Incorporating SELENIB Trial) [QOL]

Study ID: NCT00553215

Conditions

Bladder Cancer

Interventions

quality-of-life assessment

questionnaire administration

Study Description

Brief Summary: RATIONALE: Studying quality of life in patients with bladder cancer may help determine the long-term effects of bladder cancer and may help improve the quality of life for patients in the future. PURPOSE: This clinical trial is studying quality of life in patients with bladder cancer.

Detailed Description: OBJECTIVES: * To study the effects of recurrence and progression on health-related quality of life (HRQL). * To study the effects of repeat cystoscopy on HRQL. * To study the patients' assessments of a hypothetical prognostic model and how this affects their preference for the mode of surveillance. OUTLINE: This is a multicenter study. Quality-of-life questionnaires developed by the European Organization for Research and Treatment for Cancer (EORTC) will be used. The EORTC QLQ-BLS24 with 24 questions specific to non-muscle-invasive bladder cancer and the EORTC QLQ-BLM30 with 30 questions specific to muscle-invasive bladder cancer will be combined and used in conjunction with the general cancer questionnaire QLQ-C30. Assessments using the QLQ-C30 will be made at baseline in the entire cohort of patients. Follow-up assessments using the QLQ-C30, QLQ-BLS24, and QLQ-BLM30 167 will be made at first routine follow-up and annually until the end of study. Peer Reviewed and Funded or Endorsed by Cancer Research UK.